{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:34:19Z","timestamp":1780461259893,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s10549-013-2454-9","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T01:22:49Z","timestamp":1362532969000},"page":"621-631","source":"Crossref","is-referenced-by-count":21,"title":["Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy"],"prefix":"10.1007","volume":"138","author":[{"given":"Victoria M.","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jau","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"issue":"10","key":"2454_CR1","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. doi: 10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"9","key":"2454_CR2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916\u20131924. doi: 10.1002\/cncr.20983","journal-title":"Cancer"},{"issue":"23","key":"2454_CR3","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116(23):5555\u20135563. doi: 10.1002\/cncr.25332","journal-title":"Cancer"},{"issue":"1","key":"2454_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1(1):23\u201335. doi: 10.3816\/SCT.2003.n.002","journal-title":"Support Cancer Ther"},{"issue":"1","key":"2454_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM198101013040103","volume":"304","author":"G Bonadonna","year":"1981","unstructured":"Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10\u201315","journal-title":"N Engl J Med"},{"issue":"16","key":"2454_CR6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","volume":"90","author":"DR Budman","year":"1998","unstructured":"Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E 3rd (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J Natl Cancer Inst 90(16):1205\u20131211. doi: 10.1093\/jnci\/90.16.1205","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2454_CR7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","volume":"114","author":"I Chirivella","year":"2009","unstructured":"Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114(3):479\u2013484. doi: 10.1007\/s10549-008-0018-1","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2454_CR8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/11592980-000000000-00000","volume":"30","author":"SL Michels","year":"2012","unstructured":"Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH (2012) Costs associated with febrile neutropenia in the US. Pharmacoeconomics 30(9):809\u2013823. doi: 10.2165\/11592980-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"2454_CR9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","volume":"29A","author":"V Trillet-Lenoir","year":"1993","unstructured":"Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A(3):319\u2013324","journal-title":"Eur J Cancer"},{"issue":"6","key":"2454_CR10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184. doi: 10.1200\/JCO.2005.09.102","journal-title":"J Clin Oncol"},{"issue":"1","key":"2454_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. doi: 10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"2454_CR12","unstructured":"NCCN (2012) Myeloid growth factors. NCCN Clinical Practice Guidelines in Oncology v1.2012"},{"issue":"5","key":"2454_CR13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","volume":"144","author":"R Pettengell","year":"2009","unstructured":"Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational European neutropenia study. Br J Haematol 144(5):677\u2013685. doi: 10.1111\/j.1365-2141.2008.07514.x","journal-title":"Br J Haematol"},{"issue":"5 Suppl 4","key":"2454_CR14","first-page":"22","volume":"20","author":"J Crawford","year":"2006","unstructured":"Crawford J (2006) Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. Oncology (Williston Park) 20(5 Suppl 4):22\u201328","journal-title":"Oncology (Williston Park)"},{"issue":"17","key":"2454_CR15","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1200\/JCO.2002.12.113","volume":"20","author":"GK Ellis","year":"2002","unstructured":"Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T (2002) Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 20(17):3637\u20133643","journal-title":"J Clin Oncol"},{"issue":"6","key":"2454_CR16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6):427\u2013437. doi: 10.1634\/theoncologist.10-6-427","journal-title":"Oncologist"},{"issue":"4","key":"2454_CR17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejca.2008.11.021","volume":"45","author":"G Minckwitz von","year":"2009","unstructured":"von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 45(4):608\u2013617. doi: 10.1016\/j.ejca.2008.11.021","journal-title":"Eur J Cancer"},{"issue":"1","key":"2454_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/SCT.2005.n.023","volume":"3","author":"J Crawford","year":"2005","unstructured":"Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H (2005) Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 3(1):36\u201346. doi: 10.3816\/SCT.2005.n.023","journal-title":"Support Cancer Ther"},{"key":"2454_CR19","author":"W Hosmer","year":"2010","unstructured":"Hosmer W, Malin J, Wong M (2010) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. doi: 10.1007\/s00520-010-0821-1","journal-title":"Support Care Cancer"},{"issue":"4","key":"2454_CR20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","volume":"19","author":"M Schwenkglenks","year":"2011","unstructured":"Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A, Szucs TD, Leonard R (2011) Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU prospective observational European neutropenia study. Support Care Cancer 19(4):483\u2013490. doi: 10.1007\/s00520-010-0840-y","journal-title":"Support Care Cancer"},{"issue":"3","key":"2454_CR21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","volume":"16","author":"C Koebnick","year":"2012","unstructured":"Koebnick C, Langer-Gould AM, Michael K, Gould MK, Chao CR, Iyer RL, Smith N, Wansu Chen W, Jacobsen SJ (2012) Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 16(3):37\u201341","journal-title":"Perm J"},{"issue":"3","key":"2454_CR22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","volume":"98","author":"RJ Glynn","year":"2006","unstructured":"Glynn RJ, Schneeweiss S, Sturmer T (2006) Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 98(3):253\u2013259. doi: 10.1111\/j.1742-7843.2006.pto_293.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4 Suppl 13","key":"2454_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0093-7754(03)00315-4","volume":"30","author":"H Ozer","year":"2003","unstructured":"Ozer H (2003) New directions in the management of chemotherapy-induced neutropenia: risk models, special populations, and quality of life. Semin Oncol 30(4 Suppl 13):18\u201323","journal-title":"Semin Oncol"},{"issue":"12","key":"2454_CR24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/1042819031000119262","volume":"44","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44(12):2069\u20132076","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2454_CR25","first-page":"78","volume":"169","author":"RA O\u2019Reilly","year":"1998","unstructured":"O\u2019Reilly RA (1998) Splenomegaly in 2,505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2,056 patients. West J Med 169(2):78\u201387","journal-title":"West J Med"},{"key":"2454_CR26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.7326\/0003-4819-16-6-1097","volume":"16","author":"BK Wiseman","year":"1942","unstructured":"Wiseman BK, Doan CA (1942) A newly recognized granulopenic syndrome caused by excessive splenic leukolysis and successfully treated by splenectomy. Ann Intern Med 16:1097","journal-title":"Ann Intern Med"},{"issue":"1","key":"2454_CR27","first-page":"107","volume":"14","author":"Y Tomer","year":"1993","unstructured":"Tomer Y, Davies TF (1993) Infection, thyroid disease, and autoimmunity. Endocr Rev 14(1):107\u2013120","journal-title":"Endocr Rev"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2454-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2454-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2454-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:47:13Z","timestamp":1559220433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2454-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,7]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2454"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2454-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,7]]}}}